



**HAL**  
open science

# Origin, evolution and innate immune control of simian foamy viruses in humans

Rejane Rua, Antoine Gessain

► **To cite this version:**

Rejane Rua, Antoine Gessain. Origin, evolution and innate immune control of simian foamy viruses in humans. *Current Opinion in Virology*, 2015, 10, pp.47-55. 10.1016/j.coviro.2014.12.003. hal-04826381

**HAL Id: hal-04826381**

**<https://hal.science/hal-04826381v1>**

Submitted on 18 Dec 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Origin, evolution and innate immune control of simian foamy viruses in humans

Rejane Rua<sup>1,2,3,4</sup> and Antoine Gessain<sup>1,2,3</sup>



Most viral pathogens that have emerged in humans have originated from various animal species. Emergence is a multistep process involving an initial spill-over of the infectious agent into single individuals and its subsequent dissemination into the human population. Similar to simian immunodeficiency viruses and simian T lymphotropic viruses, simian foamy viruses (SFV) are retroviruses that are widespread among non-human primates and can be transmitted to humans, giving rise to a persistent infection, which seems to be controlled in the case of SFV. In this review, we present current data on the discovery, cross-species transmission, and molecular evolution of SFV in human populations initially infected and thus at risk for zoonotic emergence.

## Addresses

<sup>1</sup> Institut Pasteur, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, 28 Rue du Dr. Roux, 75015 Paris, France

<sup>2</sup> Département de Virologie, Institut Pasteur, 25-28 rue du Dr Roux, 75724 Paris, Cedex 15, France

<sup>3</sup> CNRS, UMR369, 28 Rue du Dr. Roux, F-75015 Paris, France

<sup>4</sup> Université Paris Diderot, Cellule Pasteur, Paris, France

Corresponding author: Rua, Rejane ([rejane.rua@nih.gov](mailto:rejane.rua@nih.gov))

Current Opinion in Virology 2015, 10:47–55

This review comes from a themed issue on **Emerging viruses: interspecies transmission**

Edited by **Antoine Gessain** and **Fernando Garcia-Arenal**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 17th February 2015

<http://dx.doi.org/10.1016/j.coviro.2014.12.003>

1879-6257/© 2014 Elsevier B.V. All rights reserved.

Most viral pathogens that have emerged in humans during the last century are thought to have originated from various animal species and are thus of zoonotic origin [1]. While the modes of viral dissemination within the human population are generally well characterized, the initial steps at the interspecies interface that lead to viral emergence remain poorly understood. Epidemiological field studies conducted in certain specific high-risk populations are thus crucial to obtain new insights into these early events of the emergence process.

Human infections by simian viruses represent an increasing public health concern. Indeed, non-human primates (NHPs) are considered to be the likely sources of viruses

that infect humans and thus may pose a significant threat to human population [2]. This is well illustrated by some retroviruses, which have the ability to cross-species, possibly adapt to a new host and sometimes spread within this new species. It is now clear that the emergence of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in humans has resulted from several independent interspecies transmissions. Different SIV types from chimpanzees and gorillas in the western part of Central Africa as well as sooty mangabeys in West Africa, gave rise to HIV-1 and HIV-2 respectively, probably during the first part of the last century [2]. Similarly, the origin of most Human T cell Lymphotropic virus type 1 (HTLV-1) subtypes appears to be linked to interspecies transmission between STLV-1-infected monkeys and humans, followed by variable periods of evolution in the human host [2]. In this brief review, we will present the current available data on the discovery, cross-species transmission and molecular evolution of the simian foamy viruses (SFV) present in different human populations at risk for zoonotic emergence.

## Simian foamy viruses in humans

Since the initial description of foamy virus (FV) in rhesus monkey kidney cells in 1954 [3], such viruses have been isolated from several animal species, including numerous NHP species. The prevalence of FVs in naturally infected animals is generally high, but varies widely according to species [2]. Among NHP populations, SFV seroprevalence can reach up to 75–100% in adults [2]. In African green monkey and macaques, oral mucosa tissue is an important site for viral replication, explaining why foamy viral RNA is found at a high concentration in the saliva of such primates [4••]. Saliva-based means of transmission, such as bites, have been thus strongly suggested. Infection by SFV itself does not seem to cause any disease in infected NHPs, but studies have not been conducted to address this question specifically. However, when considering co-infections in macaques, SFV can increase the pathogenicity of simian immunodeficiency virus [5].

In 1971, the first human foamy virus was isolated from the cell culture of a Kenyan patient suffering of nasopharyngeal carcinoma [6]. Phylogenetic studies demonstrated that this virus originated from the East African chimpanzee subspecies (*Pan troglodytes schweinfurtii*). This strain is now considered to be the 'prototype foamy virus' (PFV). However, its exact origin remains unclear (*in vivo* cross-species transmission from a chimpanzee to the African

patient, or cell culture contamination) [7]. In the 1970/80s, several papers showed conflicting results on the presence of SFV in human populations and in different patients [8,9]. These findings reflected the high percentage of non-specific serological reactivity and the lack of specific confirmatory tests at that time.

In 1995, based on specific serological and molecular assays, the first clear evidence of SFV in Humans was reported among 3 laboratory and monkey house personnel [10\*\*]. Since then, other groups have reported similar findings in a series of workers occupationally exposed to NHPs in the USA and Canada and more recently in personnel from zoos or primate centers in Gabon and China [8]. Infection by SFV in a more natural setting was then demonstrated in villagers from Cameroon [11]. They were mostly hunters who reported direct contacts with blood and/or body fluids from wild NHPs. We extended such studies into different areas and populations of this Central African country and found the presence of SFV infection in at least 50 persons [12\*\*]. The great majority of them (Bantus or Pygmies) were men who had been bitten by an ape (mostly gorillas but also chimpanzees) or a small monkey (mostly *Cercopithecus nictitans*) during hunting activities. A recent report from Gabon confirmed such frequent cross-species transmission in hunters after severe bites from mostly gorilla [13]. Infected women were also recently found in the Democratic Republic of Congo [14]. In South and Southeast Asian countries, SFV zoonotic infection has also been detected in various contexts of interspecies contact including ‘monkey temple’ workers, pet owners and people living around free-ranging macaques in South and Southeast Asia [15]. It is interesting to note that the Human/NHP interface in Asia differs greatly from that in Africa [16]. Human and macaques sympatry in Southeast Asia dates back as far as 25,000 years. Human-macaque commensalism is frequent in many monkey temples of these regions each year putting a very large number of persons, including tourists, at risk for macaques bites [17]. Indeed, human subjects in


some South Asian countries came into contact with rhesus macaques mostly in the context of their daily lives, sharing a geographical area that is the ‘home range’ of both primate populations [16]. Such frequent interactions can lead to possible viral interspecies transmission. The situation is very different in central Africa where bushmeat hunting (including Apes such as gorillas and chimpanzees) is the major risk factor associated with SFV interspecies transmission [12\*\*]. Furthermore, in Central Africa, the number of contacts between humans (mostly hunters and their wives and butchers) and potentially infected NHPs has probably greatly increased during the last century. This is believed to be due to increased hunting activities, resulting from a combination of urban demand for bushmeat, greater access to NHP habitats provided in part by logging roads, easier accessibility to fire arms, an increase in populations living in forest areas, and the associated increase in local food needs [2].

While nowadays, Humans are not considered to be a natural host of SFV, more than 100 cases of SFV infection have been reported so far in individuals in close contact with NHPs [8]. Among them, no specific pathology has been yet demonstrated. However, the selection bias inherent in the enrollment of healthy persons in the very few performed studies greatly limits the current ability to identify any potential associated disease.

### SFV genomic organization and structural proteins

The SFV genome comprises the retroviral *gag*, *pol* and *env* genes, and two regulatory genes *tas* and *bet*. An internal promoter allows basal transcription of *tas* and *bet* (Figure 1). The transactivator Tas then activates a second promoter located in the long-terminal repeat, which induces the synthesis of the Gag, Pol and Env structural proteins. SFVs can also go through a late reverse transcription step, before the release of SFV particles. Thus, SFV particles can contain SFV RNA and SFV DNA genomes (Figure 2A) [18].

Figure 1



**Schematic representation of SFV genomic organization (chimpanzee strain).** The SFV genome is flanked by two long terminal repeat (LTRs) which contain the unique 3' (U3), repeated (R) and unique 5' (U5) regions. *gag* encodes the full-length gag protein (74 kDa) and the shorter p70 protein. *pol* encodes the protease (PR)-reverse transcriptase (RT)-Rnase H protein and the integrase (INT). *env* encodes the leader peptide (LP), the surface glycoprotein (SU) and the transmembrane protein (TM). Two additional genes *tas* and *bet* encode proteins having regulatory functions. The transactivator Tas binds to the 5'LTR which activates the transcription of the structural genes *gag*, *pol* and *env*.

Figure 2







Figure 3



**Observation of SFV and SFV-infected cells.** BHK-21 cells were infected with a chimpanzee SFV strain isolated from an SFV-infected hunter [31]. A large syncytium with a 'foamy' aspect is visible using light microscopy (A). An immunofluorescent staining was performed as previously described [62]. SFV antigens are revealed in the green channel and nuclei are stained with DAPI (B). U87MG cells were infected by SFV-1 and used for electron microscopy (C,D). Scale bars represent 10  $\mu\text{m}$  (A), 3  $\mu\text{m}$  (B) or 300 nm (C,D).

### SFV tropism

*In vitro*, SFV can infect most cell types. Heparan sulfates represent attachment factors [19]. However, an SFV receptor has not yet been discovered and is probably ubiquitous. Once productively infected, cells usually form syncytia with a 'foam-like' cytopathic effect, before cell death occurs (Figure 3, A to D). However, some cell lines as well as primary cells of the myeloid or lymphoid lineage can remain chronically infected [20,21]. In NHPs, SFV is latent in blood cells and replicates in the superficial epithelial layer of the oral mucosa [4<sup>\*\*</sup>,22], which explains the mode of transmission of SFV to humans, mainly through bites [12<sup>\*\*</sup>]. Viral genomes in the buccal swab usually reflects those found in the blood [23]. In

humans, SFV is also present in PBMCs and saliva. However, no active replication, as monitored by SFV RNA, has been detected in the PBMCs nor in the saliva [24].

In the blood, the cellular targets of SFV remain poorly studied. Preliminary studies, performed mostly in small series of chimpanzees, African green monkeys, and in few humans, have shown SFV DNA in lymphocytes, especially CD8<sup>+</sup> T cells [25,26]. By studying a larger cohort of humans infected with a gorilla strain of SFV in Cameroon, we demonstrated that CD8<sup>+</sup>, CD4<sup>+</sup> T cells and CD19<sup>+</sup> B lymphocytes were preferentially infected, compared to monocytes and NK cells (Table 1). SFV DNA was detected in both memory and naive CD4<sup>+</sup> T lymphocytes and SFV DNA levels in CD4<sup>+</sup> T cells were positively correlated with the duration of the infection [27].

### SFV genetic stability

SFV genomes display a high evolutionary conservation among all the species infected and SFV genetic variability within one infected animal is very low over time (<1% variation over 13 years) [28]. This genetic stability might be explained by the long co-evolution with their host [29<sup>\*</sup>] and their subsequent efficient adaptation. SFV genetic stability could also prevent or delay infection of new hosts as molecular changes may be required to infect cells from a different species and/or evade host-specific immune responses [30]. Genetic stability was also found in SFV-infected humans, with less than 1% divergence in the nucleotide sequence over several years [13,24]. Several groups also reported genetic modifications including mutations in the Bet accessory gene [25,31], deletion in the U3 sequence of the LTR which improves FV replication *in vitro* [31,32] and deletions in the Tas sequence, which might be linked with the chronicity of the infection [31]. However, most of these modifications are not a unifying trait of zoonotic strains, and can also be found in NHP or experimentally infected animals [31]. This suggests that viral strains remain mainly stable, even decades after cross-species transmission. This is probably related to the apparent low level of SFV replication in infected humans, which could be linked with their efficient immune control.

**(Figure 2 Legend) Mechanisms of action of antiviral factors against FV.** (A) SFV life cycle starts with infection of a new cell by SFV particles containing RNA and/or DNA, decapsidation of the viral genome, reverse transcription of RNA genomes and integration of viral DNA into cellular DNA. Cellular activation of the internal promoter induces *tas* and *bet* transcription. The transactivator Tas then activates a second promoter located in the long-terminal repeat, which induces the synthesis of the Gag, Pol and Env structural proteins. After assembling, viral particles bud essentially from the endoplasmic reticulum, with a late reverse-transcription step giving rise to both DNA and RNA particles. (B) SFV is detected by plasmacytoid dendritic cells (not exclusively) which triggers IFN-I production. Several antiviral factors that can be induced by IFN-I are active against SFV. TRIM5 $\alpha$  are antiviral proteins that prevent SFV decapsidation [50]. Apolipoprotein B-editing catalytic polypeptide-like subunit (APOBEC) enzymes act on the negative strand DNA produced by the viral reverse transcriptase, resulting in G-to-A mutations in the viral genome, with potential deleterious consequences. FV Bet protein has been shown to partially prevent APOBEC action [40–43]. N-Myc interactor (NMI) as well as a member of the interferon-induced protein (IFP) family, IFP35, can inhibit the replication of the prototype and the bovine FV respectively, by direct interaction with the viral transactivator Tas [46,47]. Tetherin is known to block many different types of enveloped viruses by tethering the budding virus at the cell membrane and is also efficient to prevent FV release [48,49].

**Table 1**

**SFV tropism and viral load in the blood of SFV-infected humans and NHPs. The proportion of SFV DNA positive samples among leukocyte populations in SFV-infected NHP and SFV-infected humans is indicated.**

Host	Infecting strain	Read-out for SFV DNA detection	Quantification method	SFV DNA detection and load in sorted white blood cell populations from SFV-infected individuals						Refs
				CD8+ T lymphocytes	CD4+ T lymphocytes	CD19+ B lymphocytes	CD14+ monocytes	CD56+ NK lymphocytes	Granulocytes	
AGM	SFV-3	Nb. of SFV DNA + samples/ind. tested		9/9	1/3	NT <sup>a</sup>	2/7	NT <sup>a</sup>	1/7	[26]
		SFV DNA copies/number of cells	Semi-quant. PCR (serial dilutions)	≈1–100 SFV DNA/10 <sup>5</sup> cells	≈10 SFV DNA/10 <sup>5</sup> cells	NT <sup>a</sup>	≈1 SFV DNA/10 <sup>5</sup> cells	NT <sup>a</sup>	≈1 SFV DNA/10 <sup>5</sup> cells	[26]
CPZ	SFV-6	Nb. of SFV DNA + samples/ind. tested		4/4	3/4	NT <sup>a</sup>	1/4	NT <sup>a</sup>	3/4	[26]
		SFV DNA copies/number of cells	Semi-quant. PCR (serial dilutions)	≈1 SFV DNA/10 <sup>5</sup> cells	≈1–10 SFV DNA/10 <sup>5</sup> cells	NT <sup>a</sup>	≈1 SFV DNA/10 <sup>5</sup> cells	NT <sup>a</sup>	≈1 SFV DNA/10 <sup>5</sup> cells	[26]
Hum.	SFV-3 or HFV	Nb. of SFV DNA + samples/ind. tested		2/2	0/2	NT <sup>a</sup>	0/2	NT <sup>a</sup>	0/2	[26]
		SFV DNA copies/number of cells	Semi-quant. PCR (serial dilutions)	≈1–10 SFV DNA/10 <sup>5</sup> cells	NA	NT <sup>a</sup>	NA	NT <sup>a</sup>	NA	[26]
Hum.	SFV-HU1 (SFV-3)	Nb. of SFV DNA + samples/ind. tested		0/1	0/1	1/1	1/1	NT	NT	[25]
		SFV DNA copies/number of cells	Non-quant. PCR (one dilution)	NA	NA	>70 SFV DNA/10 <sup>5</sup> cells <sup>b</sup>	>70 SFV DNA/10 <sup>5</sup> cells <sup>b</sup>	NA	NA	[25]
Hum.	SFVgor	Nb of SFV DNA + samples/ind. tested		10/11	9/11	7/11	2/11	1/11	NT	[27]
		SFV DNA copies/number of cells	Quantitative PCR	6–274 SFV DNA/10 <sup>5</sup> cells	6–61 SFV DNA/10 <sup>5</sup> cells	10–91 SFV DNA/10 <sup>5</sup> cells	4–5 SFV DNA/10 <sup>5</sup> cells	5 SFV DNA/10 <sup>5</sup> cells	NA	[27]

AGM: African green monkey; CPZ: chimpanzee; Hum.: Human; NT: Not tested; Nb.: Number; Ind.: Individuals; NA: Not applicable. SFV-HU1 is a strain close to SFV-3.

<sup>a</sup> In the study from Von Laer *et al.* [26], the population tested is actually non-CD4+ non-CD8+ lymphocytes, and is thus likely enriched in both CD19+ B and CD56+ NK lymphocytes. The proportion of positive samples are 7/9 AGM, 3/4 CPZ and 0/2 humans. SFV DNA loads in this sorted cell population is ≈1/10<sup>5</sup> cells (in the 7/9 positive samples from AGM) and ≈1/10<sup>5</sup> cells (in the 3/4 samples from CPZ).

<sup>b</sup> In the study from Callahan *et al.* [25], only one dilution of leucocytes DNA was shown, corresponding to a viral load of >70 SFV DNA copies/10<sup>5</sup> cells, assuming the usual sensitivity of 1 SFV DNA copies/10<sup>5</sup> cells.

### **In vivo super-infection and recombination of SFV**

Some groups have reported cases of co-infection by two different SFVs in apes, monkeys, as well as in humans. Some chimpanzees infected by SFVcpz strains were co-infected with SFV from colobus monkeys [33], or cercopithecus monkeys [34]. More frequently, chimpanzees and macaques can harbor distinguishable SFVcpz and SFVmac strains respectively, likely the result of multiple independent infections that accumulate with age [16,35,36]. SFVcpz infection appears to first occur *via* vertical transmission but is followed in adult life by the acquisition of further infections, possibly stemming from aggressive interactions [35]. In some of these studies, as well as in a recent one, some SFV appears to be recombinant strains [34,36,37]. We, and others, have found different clones of SFV in single individuals [12<sup>\*\*</sup>,16,24], suggesting a co-infection with multiple SFV strains. Whether they were acquired at a single time or through several contacts with NHP is not known.

### **Immune control of SFV**

#### **Innate restriction of SFV**

Interferons are potent antiviral molecules and usually represent one of the first lines of defense to pathogens. *In vitro*, SFVs were first thought to be low interferon-inducers [38] but this actually depends on the cell type. Indeed, we found that SFVs are efficiently sensed by human hematopoietic cells and induce the production of high levels of IFN-I [39]. The main producers of IFN-I in the blood are the plasmacytoid dendritic cells, which detect SFV genome after uptake of SFV particles, through the endosomal toll-like receptor 7 [39]. In culture systems, the addition of type I IFN impairs SFV replication, suggesting that interferon-inducible genes might be involved in the control of SFV replication (Figure 2A and B):

- Apolipoprotein B-editing catalytic polypeptide-like subunit (APOBEC) enzymes are a family of antiviral cytidine deaminases that act on the negative strand DNA produced by the viral reverse transcriptase, resulting in G-to-A mutations in the viral genome, with potential deleterious consequences. However, viruses often produce proteins that counteract cellular defense systems. FV Bet protein has been shown to prevent APOBEC action [40–43]. Despite the action of Bet, it was reported that SFV genomes found in humans displayed some G-to-A mutations [24,44]. Matsen et al. found that the frequency and the type of hypermutations were different in humans and macaques, with a majority of hypermutations leading to stop codons in humans, suggesting active restriction of the infecting strain in humans and not only passive acquisition of previously mutated strain [45<sup>\*</sup>].

Additional studies have been performed *in vitro* to elucidate the mechanisms involved in the control of SFV

replication, although their relevance *in vivo* has not been tested so far:

- Two homologous proteins, N-Myc interactor (NMI) as well as a member of the interferon-induced protein (IFP) family, IFP35, can inhibit the replication of PFV and BFV, respectively, by direct interaction with the viral transactivator Tas [46,47].
- Tetherin is known to block many different types of enveloped viruses by tethering the budding virus at the cell membrane and is also efficient to prevent FV release [48,49].
- TRIM5 $\alpha$  are antiviral proteins that prevent viral decapsulation [50]. They act in a species-specific manner: PFV and SFVmac are restricted by TRIM5 $\alpha$  from most New World monkeys, but not from other primates including humans. This indicates that TRIM5 $\alpha$  is probably not involved in the restriction of SFV after cross-species transmission from chimpanzees and macaques to humans, at least nowadays [51].

Of note, some known antiretroviral factors are not potent against SFV. For instance, as reverse transcription occurs predominantly before entry into target cell, these viruses are resistant to the dNTP levels reduction by SAMHD1 [52].

#### **Adaptative restriction of SFV**

Few studies have addressed the question of adaptative immune response to SFV.

First, neutralizing antibodies present in the serum of infected animals inhibit SFV transmission and infection in rhesus macaques [53], indicating a role of the adaptive immune response in the control of SFV *in vivo*. This is further supported by the fact that antibodies titers in feces of chimpanzees infected with SFV are inversely correlated with SFV viral load [34]. However, very few data are available concerning the adaptative immune response to SFV in humans. Antibodies against SFV are detected in the blood of infected individuals and were also found in saliva and urine samples in four SFV-infected individuals tested. However, antibody titers were lower than in infected chimpanzees, which could be linked to lower levels of SFV replication in humans [54]. Neutralization of SFV by sera from three SFVagm-infected individuals was reported in 1983 and 1997 [55,56].

Secondly, neutralization of IFN-gamma in activated PBMCs infected with SFV, increases viral expression [57] and SFV up-regulates MHC-I *in vitro* [58], suggesting that adaptative immunity might be elicited and efficient in the control of SFV in infected individuals. Although virus-specific T lymphocytes are key effectors that control the outcome of HTLV and HIV infection [59], no report has addressed their presence in SFV-infected NHPs or humans.



## Conclusion

Human infection by SFV constitutes a unique natural model to study the various parameters involved in restriction of retroviral emergence. The future of SFV emergence in humans remains an open question. However, the current increase in NHP-to-human contacts (in part due to hunting activities and animal handling) may favor such cross-species transmission [2]. Furthermore, other factors such as SFV co-infection with HIV, already reported in Cameroon [60], may increase the risk of SFV pathogenicity and will require further investigation. Nevertheless, any prediction concerning viral emergence remains very difficult and hazardous, as recently exemplified by Ebola and MERS coronavirus outbreaks in West Africa and Saudi Arabia respectively [61]. In this regard, intensive research on mechanisms of the first steps of viral emergence should be further developed.

## Conflict of interest

The authors declare no competing financial interests.

## Acknowledgements

RR was supported by the Bourse de l'École Normale Supérieure from the Faculté Paris Diderot. This work was supported by the Institut Pasteur in Paris, France, by Programme Transversal de Recherche 437 from the Institut Pasteur, and by the French government program Investissement d'Avenir (grant ANR-10-LABX-62-IBEID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Wolfe ND, Dunavan CP, Diamond J: **Origins of major human infectious diseases.** *Nature* 2007, **447**:279-283.
2. Locatelli S, Peeters M: **Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population.** *AIDS* 2012, **26**:659-673.
3. Enders JF, Peebles TC: **Propagation in tissue cultures of cytopathogenic agents from patients with measles.** *Proc Soc Exp Biol Med* 1954, **86**:277-286.
4. Murray SM, Picker LJ, Axthelm MK, Hudkins K, Alpers CE, Linal ML: **Replication in a superficial epithelial cell niche explains the lack of pathogenicity of primate foamy virus infections.** *J Virol* 2008, **82**:5981-5985.
5. Choudhary A, Galvin TA, Williams DK, Beren J, Bryant MA, Khan AS: **Influence of naturally occurring simian foamy viruses (SFVs) on SIV disease progression in the rhesus macaque (*Macaca mulatta*) model.** *Viruses* 2013, **5**:1414-1430.
6. Achong BG, Mansell PW, Epstein MA: **A new human virus in cultures from a nasopharyngeal carcinoma.** *J Pathol* 1971, **103**:P18.
7. Murray SM, Linal ML: **Foamy virus infection in primates.** *J Med Primatol* 2006, **35**:225-235.
8. Gessain A, Rua R, Betsem E, Turpin J, Mahieux R: **HTLV-3/4 and simian foamy retroviruses in humans: discovery, epidemiology, cross-species transmission and molecular virology.** *Virology* 2013, **435**:187-199.
9. Meiering CD, Linal ML: **Historical perspective of foamy virus epidemiology and infection.** *Clin Microbiol Rev* 2001, **14**:165-176.
10. Schweizer M, Turek R, Hahn H, Schliephake A, Netzer KO, Eder G, Reinhardt M, Rethwilm A, Neumann-Haefelin D: **Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans.** *AIDS Res Hum Retroviruses*. 1995, **11**:161-170.
11. Wolfe ND, Switzer WM, Carr JK, Bhullar VB, Shanmugam V, Tamoufe U, Prosser AT, Torimiro JN, Wright A, Mpoudi-Ngole E *et al.*: **Naturally acquired simian retrovirus infections in central African hunters.** *Lancet* 2004, **363**:932-937.
12. Betsem E, Rua R, Tortevoeye P, Froment A, Gessain A: **Frequent and recent human acquisition of simian foamy viruses through apes' bites in central Africa.** *PLoS Pathog* 2011, **7**:e1002306.
13. Mouinga-Ondeme A, Caron M, Nkoghe D, Telfer P, Marx P, Saib A, Leroy E, Gonzalez JP, Gessain A, Kazanji M: **Cross-species transmission of simian foamy virus to humans in rural Gabon, Central Africa.** *J Virol* 2012, **86**:1255-1260.
14. Switzer WM, Tang S, Ahuka-Mundeki S, Shankar A, Hanson DL, Zheng H, Ayouba A, Wolfe ND, LeBreton M, Djoko CF *et al.*: **Novel simian foamy virus infections from multiple monkey species in women from the Democratic Republic of Congo.** *Retrovirology* 2012, **9**:100.
15. Jones-Engel L, May CC, Engel GA, Steinkraus KA, Schillaci MA, Fuentes A, Rompis A, Chalise MK, Aggimarangsee N, Feeroz MM *et al.*: **Diverse contexts of zoonotic transmission of simian foamy viruses in Asia.** *Emerg Infect Dis* 2008, **14**:1200-1208.
16. Engel GA, Small CT, Soliven K, Feeroz MM, Wang XX, Hasan MK, Oh G, Alam SMR, Craig KL, Jackson DL *et al.*: **Zoonotic simian foamy virus in Bangladesh reflects diverse patterns of transmission and co-infection.** *Emerg Microbes Infect* 2013:2.
17. Jones-Engel L, Engel GA, Schillaci MA, Rompis A, Putra A, Suaryana KG, Fuentes A, Beer B, Hicks S, White R *et al.*: **Primate-to-human retroviral transmission in Asia.** *Emerg Infect Dis* 2005, **11**:1028-1035.
18. Rethwilm A: **Molecular biology of foamy viruses.** *Med Microbiol Immunol* 2010, **199**:197-207.
19. Plochmann K, Horn A, Gschmack E, Armbruster N, Krieg J, Wiktorowicz T, Weber C, Stirnagel K, Lindemann D, Rethwilm A *et al.*: **Heparan sulfate is an attachment factor for foamy virus entry.** *J Virol* 2012, **86**:10028-10035.
20. Mikovits JA, Hoffman PM, Rethwilm A, Ruscetti FW: **In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.** *J Virol* 1996, **70**:2774-2780.
21. Yu SF, Stone J, Linal ML: **Productive persistent infection of hematopoietic cells by human foamy virus.** *J Virol* 1996, **70**:1250-1254.
22. Murray SM, Picker LJ, Axthelm MK, Linal ML: **Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression.** *J Virol* 2006, **80**:663-670.
23. Soliven K, Wang X, Small CT, Feeroz MM, Lee EG, Craig KL, Hasan K, Engel GA, Jones-Engel L, Matsen FA *et al.*: **Simian foamy virus infection of rhesus macaques in Bangladesh: relationship of latent proviruses and transcriptionally active viruses.** *J Virol* 2013, **87**:13628-13639.
24. Rua R, Betsem E, Gessain A: **Viral latency in blood and saliva of simian foamy virus-infected humans.** *PLoS One* 2013, **8**:e77072.

25. Callahan ME, Switzer WM, Matthews AL, Roberts BD, Heneine W, Folks TM, Sandstrom PA: **Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene.** *J Virol* 1999, **73**:9619-9624.
26. von Laer D, Neumann-Haefelin D, Heeney JL, Schweizer M: **Lymphocytes are the major reservoir for foamy viruses in peripheral blood.** *Virology* 1996, **221**:240-244.
27. Rua R, Betsem E, Montange T, Buseyne F, Gessain A: **In vivo cellular tropism of gorilla simian foamy virus in blood of infected humans.** *J Virol* 2014, **88**:13429-13435.
28. Schweizer M, Schleier H, Pietrek M, Liegibel J, Falcone V, Neumann-Haefelin D: **Genetic stability of foamy viruses: long-term study in an African green monkey population.** *J Virol* 1999, **73**:9256-9265.
29. Switzer WM, Salemi M, Shanmugam V, Gao F, Cong ME, Kuiken C, Bhullar V, Beer BE, Vallet D, Gautier-Hion A *et al.*: **Ancient co-speciation of simian foamy viruses and primates.** *Nature* 2005, **434**:376-380.
- This important study sets the date of cospeciation between foamy viruses and primates as far as 30 MY. The recent discovery of endogenous viruses, and FV in fishes, pushed the cospeciation date to even more than 400 MY.
30. Cleaveland S, Haydon DT, Taylor L: **Overviews of pathogen emergence: which pathogens emerge, when and why?** *Curr Top Microbiol Immunol* 2007, **5(3)**:85-111.
31. Rua R, Betsem E, Calattini S, Saib A, Gessain A: **Genetic characterization of simian foamy viruses infecting humans.** *J Virol* 2012, **86**:13350-13359.
32. Schmidt M, Herchenroder O, Heeney J, Rethwilm A: **Long terminal repeat U3 length polymorphism of human foamy virus.** *Virology* 1997, **230**:167-178.
33. Leendertz FH, Zirkel F, Couacy-Hymann E, Ellerbrok H, Morozov VA, Pauli G, Hedemann C, Formenty P, Jensen SA, Boesch C *et al.*: **Interspecies transmission of simian foamy virus in a natural predator-prey system.** *J Virol* 2008, **82**:7741-7744.
34. Liu W, Worobey M, Li Y, Keele BF, Bibollet-Ruche F, Guo Y, Goepfert PA, Santiago ML, Ndjingo JB, Neel C *et al.*: **Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees.** *PLoS Pathog* 2008, **4**:e1000097.
35. Blasse A, Calvignac-Spencer S, Merkel K, Goffe AS, Boesch C, Mundry R, Leendertz FH: **Mother-offspring transmission and age-dependent accumulation of simian foamy virus in wild chimpanzees.** *J Virol* 2013, **87**:5193-5204.
36. Feeroz MM, Soliven K, Small CT, Engel GA, Pacheco A, Yee J, Wang XX, Hasan MK, Oh G, Levine K *et al.*: **Population dynamics of rhesus macaques and associated foamy virus in Bangladesh.** *Emerg Microbes Infect* 2013, **2**:e29.
37. Galvin TA, Ahmed IA, Shahabuddin M, Bryan T, Khan AS: **Identification of recombination in the envelope gene of simian foamy virus serotype 2 isolated from *Macaca cyclopis*.** *J Virol* 2013, **87**:8792-8797.
38. Sabile A, Rhodes-Feuillette A, Jaoui FZ, Tobaly-Tapiero J, Giron ML, Lasneret J, Peries J, Canivet M: **In vitro studies on interferon-inducing capacity and sensitivity to IFN of human foamy virus.** *Res Virol* 1996, **147**:29-37.
39. Rua R, Lepelley A, Gessain A, Schwartz O: **Innate sensing of foamy viruses by human hematopoietic cells.** *J Virol* 2012, **86**:909-918.
40. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR: **Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.** *J Virol* 2005, **79**:8724-8731.
41. Lochelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rosler U, Battenberg M, Saib A *et al.*: **The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.** *Proc Natl Acad Sci U S A* 2005, **102**:7982-7987.
42. Perkovic M, Schmidt S, Marino D, Russell RA, Stauch B, Hofmann H, Kopietz F, Kloke BP, Zielonka J, Strover H *et al.*: **Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.** *J Biol Chem* 2009, **284**:5819-5826.
43. Jaguva Vasudevan AA, Perkovic M, Bulliard Y, Cichutek K, Trono D, Haussinger D, Munk C: **Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3 G.** *J Virol* 2013, **87**:9030-9040.
44. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, Froment A, Wain-Hobson S, Gessain A, Vartanian JP, Schwartz O: **Restriction of foamy viruses by APOBEC cytidine deaminases.** *J Virol* 2006, **80**:605-614.
45. Matsen FAT, Small CT, Soliven K, Engel GA, Feeroz MM, Wang X, Craig KL, Hasan MK, Emerman M, Linial ML *et al.*: **A novel Bayesian method for detection of APOBEC3-mediated hypermutation and its application to zoonotic transmission of simian foamy viruses.** *PLoS Comput Biol* 2014, **10**:e1003493.
- This interesting study provides evidence of distinct effects of APOBEC in humans and monkeys, suggesting that mutated strains found in humans are not passively acquired from macaques but are efficiently targeted by anti-viral mechanisms in humans.
46. Hu X, Yang W, Liu R, Geng Y, Qiao W, Tan J: **N-Myc interactor inhibits prototype foamy virus by sequestering viral Tas protein in the cytoplasm.** *J Virol* 2014, **88**:7036-7044.
47. Tan J, Qiao W, Wang J, Xu F, Li Y, Zhou J, Chen Q, Geng Y: **IFP35 is involved in the antiviral function of interferon by association with the viral tas transactivator of bovine foamy virus.** *J Virol* 2008, **82**:4275-4283.
48. Xu F, Tan J, Liu R, Xu D, Li Y, Geng Y, Liang C, Qiao W: **Tetherin inhibits prototypic foamy virus release.** *Virol J* 2011, **8**:198.
49. Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN, Towers GJ, Hosie MJ, Willett BJ: **Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection.** *J Virol* 2011, **85**:5840-5852.
50. Pacheco B, Finzi A, McGee-Estrada K, Sodroski J: **Species-specific inhibition of foamy viruses from South American monkeys by New World Monkey TRIM5{alpha} proteins.** *J Virol* 2010, **84**:4095-4099.
51. Yap MW, Lindemann D, Stanke N, Reh J, Westphal D, Hanenberg H, Ohkura S, Stoye JP: **Restriction of foamy viruses by primate Trim5 alpha.** *J Virol* 2008, **82**:5429-5439.
52. Gramberg T, Kahle T, Bloch N, Wittmann S, Mullers E, Daddacha W, Hofmann H, Kim B, Lindemann D, Landau NR: **Restriction of diverse retroviruses by SAMHD1.** *Retrovirology* 2013, **10**:26.
53. Williams DK, Khan AS: **Role of neutralizing antibodies in controlling simian foamy virus transmission and infection.** *Transfusion* 2010, **50**:200-207.
54. Cummins JE Jr, Boneva RS, Switzer WM, Christensen LL, Sandstrom P, Heneine W, Chapman LE, Dezzutti CS: **Mucosal and systemic antibody responses in humans infected with simian foamy virus.** *J Virol* 2005, **79**:13186-13189.
55. Neumann-Haefelin D, Rethwilm A, Bauer G, Gudat F, zur Hausen H: **Characterization of a foamy virus isolated from *Cercopithecus aethiops* lymphoblastoid cells.** *Med Microbiol Immunol* 1983, **172**:75-86.
56. Schweizer M, Falcone V, Gange J, Turek R, Neumann-Haefelin D: **Simian foamy virus isolated from an accidentally infected human individual.** *J Virol* 1997, **71**:4821-4824.
57. Falcone V, Schweizer M, Toniolo A, Neumann-Haefelin D, Meyerhans A: **Gamma interferon is a major suppressive factor produced by activated human peripheral blood lymphocytes that is able to inhibit foamy virus-induced cytopathic effects.** *J Virol* 1999, **73**:1724-1728.
58. Colas S, Bourge JF, Wybier J, Chelbi-Alix MK, Paul P, Emanoil-Ravier R: **Human foamy virus infection activates class I major histocompatibility complex antigen expression.** *J Gen Virol* 1995, **76(Pt 3)**:661-667.

59. Bangham CR: **CTL quality and the control of human retroviral infections.** *Eur J Immunol* 2009, **39**:1700-1712.
60. Switzer WM, Garcia AD, Yang C, Wright A, Kalish ML, Folks TM, Heneine W: **Coinfection with HIV-1 and simian foamy virus in West Central Africans.** *J Infect Dis* 2008, **197**:1389-1393.
61. McCloskey B, Dar O, Zumla A, Heymann DL: **Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread.** *Lancet Infect Dis* 2014, **14**:1001-1010.
62. Calattini S, Betsem EB, Froment A, Maucelere P, Tortevoeye P, Schmitt C, Njouom R, Saib A, Gessain A: **Simian foamy virus transmission from apes to humans, rural Cameroon.** *Emerg Infect Dis* 2007, **13**:1314-1320.